| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.YFRNE.2016.09.003 |
| P698 | PubMed publication ID | 27693730 |
| P50 | author | Ana Isabel Rodriguez Perez | Q64860716 |
| P2093 | author name string | Rita Valenzuela | |
| Jose L Labandeira-Garcia | |||
| Maria J Guerra | |||
| Maria A Costa-Besada | |||
| P2860 | cites work | Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine | Q48595554 |
| Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system | Q48762421 | ||
| Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro | Q48796649 | ||
| Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats | Q48844596 | ||
| Cortical neurons expressing calcium binding proteins are spared in dementia with Lewy bodies. | Q48987930 | ||
| Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. | Q50558296 | ||
| Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. | Q50901015 | ||
| Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. | Q51505405 | ||
| Risk of Parkinson disease in women: effect of reproductive characteristics. | Q51940269 | ||
| Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. | Q52144074 | ||
| Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats. | Q53000712 | ||
| Regulation of angiotensinogen by angiotensin II in mouse primary astrocyte cultures. | Q54356901 | ||
| Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. | Q54360542 | ||
| Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group | Q70928197 | ||
| Aging‐induced proinflammatory shift in cytokine expression profile in rat coronary arteries | Q73304618 | ||
| Are ACE inhibitors a "magic bullet" against oxidative stress? | Q74553430 | ||
| NADPH oxidase | Q75301478 | ||
| Age at menopause predicts age at onset of Parkinson's disease | Q79212192 | ||
| Mitochondrial estrogen receptors--new insights into specific functions | Q79836225 | ||
| Women, hormones, and clinical trials: a beginning, not an end | Q80378200 | ||
| Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence | Q80385321 | ||
| Aging-related dysregulation of dopamine and angiotensin receptor interaction | Q87296323 | ||
| The 'window of opportunity'--should we be taking it? | Q87874187 | ||
| Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system | Q37329566 | ||
| Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. | Q37329670 | ||
| NADPH oxidases and angiotensin II receptor signaling | Q37342232 | ||
| Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon | Q37344704 | ||
| Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice | Q37375439 | ||
| Coronary heart disease of females: lessons learned from nonhuman primates | Q37453283 | ||
| The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism | Q37467929 | ||
| Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women | Q37480990 | ||
| Effects of angiotensin II receptor blockers on dementia | Q37591159 | ||
| Small but powerful: short peptide hormones and their role in autoimmune inflammation | Q37596101 | ||
| Estrogen therapy: is time of initiation critical for neuroprotection? | Q37618547 | ||
| Estrogen receptor agonists and estrogen attenuate TNF- -induced apoptosis in VSC4.1 motoneurons | Q37634021 | ||
| Renin-angiotensin system blockade and cardiovascular and renal protection | Q37681742 | ||
| Estradiol synthesis within the human brain | Q37841807 | ||
| Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease | Q37905899 | ||
| Neuroinflammation in Parkinson's disease. | Q37968058 | ||
| The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases | Q38005611 | ||
| Global consensus statement on menopausal hormone therapy. | Q38089075 | ||
| Stroke neuroprotection: oestrogen and insulin-like growth factor-1 interactions and the role of microglia | Q38114130 | ||
| Sex differences in Parkinson's disease and other movement disorders | Q38200393 | ||
| Studies of intracellular angiotensin II. | Q38259009 | ||
| Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease | Q38260925 | ||
| The role of protein clearance mechanisms in organismal ageing and age-related diseases. | Q38284376 | ||
| Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update | Q38310102 | ||
| Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. | Q38363823 | ||
| EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms | Q38486068 | ||
| Perimenopause as a neurological transition state | Q38501586 | ||
| Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: implications for aging and neurodegeneration. | Q38834345 | ||
| Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation | Q38942116 | ||
| Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. | Q38990049 | ||
| Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin. | Q39055955 | ||
| Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells | Q39067766 | ||
| South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014. | Q39130530 | ||
| Striatal dopaminergic afferents concentrate in GDNF-positive patches during development and in developing intrastriatal striatal grafts. | Q39197001 | ||
| Aging effects on the dopamine transporter expression and compensatory mechanisms. | Q46919312 | ||
| Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA. | Q46936589 | ||
| The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation | Q46937404 | ||
| Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death | Q46983619 | ||
| Estrogen modulates AT1 receptor gene expression in vitro and in vivo | Q47957759 | ||
| Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain | Q48101753 | ||
| Inability of [125I]Sar1, Ile8-angiotensin II to move between the blood and cerebrospinal fluid compartments | Q48117672 | ||
| Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. | Q48341358 | ||
| Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice | Q48349334 | ||
| Ovariectomy augments hypertension through rho-kinase activation in the brain stem in female spontaneously hypertensive rats | Q48434346 | ||
| Angiotensinogen is secreted by pure rat neuronal cell cultures | Q48444281 | ||
| Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease | Q48454986 | ||
| Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors | Q48542036 | ||
| Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons | Q48580565 | ||
| Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance | Q24609255 | ||
| The G-protein-coupled estrogen receptor GPER in health and disease | Q27013052 | ||
| Menstruation and the menopausal transition | Q27015091 | ||
| Sex differences in Parkinson's disease | Q27025107 | ||
| Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network | Q27683572 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression | Q28267569 | ||
| Oxidative stress in neurodegeneration: cause or consequence? | Q28275946 | ||
| 17β-Oestradiol anti-inflammatory effects in primary astrocytes require oestrogen receptor β-mediated neuroglobin up-regulation | Q28280172 | ||
| Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia | Q28292245 | ||
| The complexities of hormonal influences and risk of Parkinson's disease | Q28389039 | ||
| Estrogen upregulates renal angiotensin II AT1 and AT2 receptors in the rat | Q28572000 | ||
| Aging of the rat mesostriatal system: differences between the nigrostriatal and the mesolimbic compartments | Q28574535 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| Microglia-mediated neurotoxicity: uncovering the molecular mechanisms | Q29547835 | ||
| NAD(P)H oxidase: role in cardiovascular biology and disease | Q29616102 | ||
| Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis | Q30422595 | ||
| Postmenopausal estrogen use affects risk for Parkinson disease | Q30433773 | ||
| Astrocytes synthesize angiotensinogen in brain | Q30461947 | ||
| Redox imbalance | Q33206786 | ||
| Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation | Q33595388 | ||
| Estrogen: a master regulator of bioenergetic systems in the brain and body | Q33623924 | ||
| A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? | Q33625889 | ||
| Premature menopause and risk of neurological disease: basic mechanisms and clinical implications | Q33693151 | ||
| Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA. | Q33713520 | ||
| Female reproductive factors, menopausal hormone use, and Parkinson's disease | Q33756791 | ||
| Mechanisms of estrogen signaling and gene expression via GPR30 | Q33760458 | ||
| Enhanced sensitivity to acute angiotensin II is testosterone dependent in adult male growth-restricted offspring | Q33841029 | ||
| Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis | Q33866065 | ||
| GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones. | Q39336234 | ||
| Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture | Q39777367 | ||
| Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells | Q39873906 | ||
| G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane | Q40266535 | ||
| Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta | Q40534784 | ||
| Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons | Q40592671 | ||
| RhoA activation promotes transendothelial migration of monocytes via ROCK. | Q40614193 | ||
| Origin of the angiotensin II secreted by cells | Q40746693 | ||
| Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease | Q42136286 | ||
| Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis | Q42177739 | ||
| Differential role of angiotensin II receptor subtypes on endothelial superoxide formation | Q42273452 | ||
| Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia | Q42456079 | ||
| Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease | Q42478715 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease | Q42484469 | ||
| Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication | Q42492568 | ||
| Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. | Q42494845 | ||
| Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography | Q42509888 | ||
| Angiotensin II induces proliferation of cultured rat astrocytes through c-Jun N-terminal kinase | Q42523051 | ||
| Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death | Q42860960 | ||
| Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. | Q43004514 | ||
| Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice | Q43055298 | ||
| Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function | Q43281300 | ||
| Mitochondrial ATP-sensitive K(+) channels as redox signals to liver mitochondria in response to hypertriglyceridemia. | Q43286918 | ||
| Chronic estrogen treatment replaces striatal dopaminergic function in ovariectomized rats | Q43596285 | ||
| Adrenal response to angiotensin II in black hypertension: lack of sexual dimorphism | Q43744722 | ||
| Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture | Q43922358 | ||
| Effect of estrogen and AT1 receptor blocker on neointima formation | Q44167913 | ||
| Estrogen upregulates renal angiotensin II AT(2) receptors | Q44174214 | ||
| Risk tables for parkinsonism and Parkinson's disease. | Q44309519 | ||
| Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression | Q44333001 | ||
| NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. | Q44631918 | ||
| Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia | Q44726987 | ||
| Aging of the nigrostriatal system in the squirrel monkey | Q44800291 | ||
| Ovarian androgen production in postmenopausal women | Q44897806 | ||
| Biomedicine. Parkinson's--divergent causes, convergent mechanisms. | Q44904985 | ||
| Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors | Q45049892 | ||
| 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats | Q45154796 | ||
| Microglial activation and dopamine terminal loss in early Parkinson's disease | Q45237159 | ||
| Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress | Q45277137 | ||
| Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. | Q45966076 | ||
| The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons | Q46041464 | ||
| The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. | Q46107846 | ||
| Estradiol and testosterone levels are lower after oophorectomy than after natural menopause | Q46133130 | ||
| Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. | Q46306546 | ||
| Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells | Q46430957 | ||
| Dopamine and noradrenaline control distinct functions in rodent microglial cells. | Q46467964 | ||
| Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. | Q46579062 | ||
| Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. | Q46599252 | ||
| Estrogen reduces angiotensin II-induced acceleration of senescence in endothelial progenitor cells | Q46647567 | ||
| Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. | Q46680573 | ||
| Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure | Q46838172 | ||
| Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction | Q46838383 | ||
| Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research | Q33874635 | ||
| Extranuclear estrogen receptor's roles in physiology: lessons from mouse models | Q33913090 | ||
| The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. | Q33921182 | ||
| Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. | Q33925972 | ||
| Mitochondrial mechanisms of estrogen neuroprotection | Q33927797 | ||
| Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? | Q34002989 | ||
| Angiotensin II sustains brain inflammation in mice via TGF-beta | Q34028682 | ||
| A dominant negative ERβ splice variant determines the effectiveness of early or late estrogen therapy after ovariectomy in rats | Q34201028 | ||
| Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity | Q34201593 | ||
| Development of subtype-selective oestrogen receptor-based therapeutics. | Q34216817 | ||
| Proinflammatory actions of angiotensins. | Q34244757 | ||
| Estrogens, estrogen receptors, and female cognitive aging: the impact of timing | Q34269755 | ||
| Formulations of hormone therapy and risk of Parkinson's disease | Q34437648 | ||
| Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent | Q34439831 | ||
| Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. | Q34464847 | ||
| Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. | Q34467441 | ||
| Renin angiotensin system and gender differences in the cardiovascular system | Q34541898 | ||
| The intracellular renin-angiotensin system: a new paradigm | Q34629348 | ||
| Increased risk of parkinsonism in women who underwent oophorectomy before menopause. | Q34673129 | ||
| Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases | Q34784469 | ||
| Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. | Q34890677 | ||
| SIRT1 functions as an important regulator of estrogen-mediated cardiomyocyte protection in angiotensin II-induced heart hypertrophy | Q34966315 | ||
| The second brain and Parkinson's disease. | Q34999864 | ||
| Gender differences in the risk of familial parkinsonism: beyond LRRK2? | Q35037102 | ||
| Sex and the renin angiotensin system: implications for gender differences in the progression of kidney disease | Q35077657 | ||
| Inflammation and angiotensin II. | Q35099157 | ||
| Renin angiotensin system and gender differences in dopaminergic degeneration. | Q35203828 | ||
| Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. | Q35416073 | ||
| Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. | Q35613025 | ||
| The oxidant stress hypothesis in Parkinson's disease: evidence supporting it | Q35626743 | ||
| Tissue renin angiotensin systems | Q35660789 | ||
| Selective oestrogen receptor modulators differentially potentiate brain mitochondrial function | Q35689751 | ||
| Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. | Q35749627 | ||
| Hormone therapy: physiological complexity belies therapeutic simplicity | Q35786011 | ||
| Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. | Q35819219 | ||
| Reactive oxygen species and angiotensin II signaling in vascular cells -- implications in cardiovascular disease | Q35845567 | ||
| Vascular inflammation in aging | Q35984535 | ||
| NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease | Q36110357 | ||
| Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. | Q36335614 | ||
| Risk factors for Parkinson's disease may differ in men and women: an exploratory study | Q36335715 | ||
| Hormone therapy and cognitive function: is there a critical period for benefit? | Q36401053 | ||
| Is brain estradiol a hormone or a neurotransmitter? | Q36437279 | ||
| Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies | Q36500918 | ||
| Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease | Q36537780 | ||
| Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra | Q36632049 | ||
| Targeting estrogen receptor β in microglia and T cells to treat experimental autoimmune encephalomyelitis | Q36653657 | ||
| Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. | Q36663074 | ||
| Implications for estrogens in Parkinson's disease: an epidemiological approach. | Q36721786 | ||
| Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney. | Q36724537 | ||
| Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. | Q36755408 | ||
| Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression | Q36793601 | ||
| Sex differences in angiotensin II- induced hypertension | Q36803840 | ||
| Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease | Q36854132 | ||
| Central estrogen inhibition of angiotensin II-induced hypertension in male mice and the role of reactive oxygen species | Q36893252 | ||
| Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation | Q36909938 | ||
| Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons. | Q36955863 | ||
| Factors related to age at natural menopause: longitudinal analyses from SWAN. | Q36974853 | ||
| Estrogen prevents intestinal inflammation after trauma-hemorrhage via downregulation of angiotensin II and angiotensin II subtype I receptor | Q36977043 | ||
| The pathogenesis of cell death in Parkinson's disease--2007. | Q37050626 | ||
| Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition | Q37089449 | ||
| Brain renin angiotensin in disease | Q37127331 | ||
| Prevention of cardiovascular events in early menopause: a possible role for hormone replacement therapy. | Q37212555 | ||
| The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications | Q37261757 | ||
| AT2 receptors: functional relevance in cardiovascular disease. | Q37274124 | ||
| Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) | Q37291566 | ||
| Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging. | Q37327417 | ||
| P921 | main subject | dopamine | Q170304 |
| estrogen | Q277954 | ||
| P304 | page(s) | 44-59 | |
| P577 | publication date | 2016-09-29 | |
| P1433 | published in | Frontiers in Neuroendocrinology | Q15716620 |
| P1476 | title | Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration | |
| P478 | volume | 43 |
| Q33627982 | Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration |
| Q36270869 | Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells. |
| Q33740654 | Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease |
| Q47107877 | Insulin-Like Growth Factor-1 and Neuroinflammation |
| Q89662028 | Is insulin-like growth factor-1 involved in Parkinson's disease development? |
| Q90077286 | Molecular mechanisms and cellular events involved in the neuroprotective actions of estradiol. Analysis of sex differences |
| Q47686009 | Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans. |
| Q38693739 | Presence of Androgen Receptor Variant in Neuronal Lipid Rafts |
| Q55119787 | Rhes Counteracts Dopamine Neuron Degeneration and Neuroinflammation Depending on Gender and Age. |
| Q47194743 | Role of Estrogen and Other Sex Hormones in Brain Aging. Neuroprotection and DNA Repair |
| Q47095334 | Role of Sex Hormones on Brain Mitochondrial Function, with Special Reference to Aging and Neurodegenerative Diseases. |
| Q90637954 | The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis |
| Q90207854 | The Role of Sex and Sex Hormones in Neurodegenerative Diseases |
Search more.